Search

Displaying results 5791 - 5800 of 10000 in total
  1. Drug

    Meglutol

    go.drugbank.com/drugs/DB04377
    Experimental

    is the rate limiting enzyme in the biosynthesis of cholesterol. … It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which

  2. Drug

    Altretamine

    go.drugbank.com/drugs/DB00488
    ApprovedWithdrawn

    An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.

  3. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways.

  4. Drug

    Alisertib

    go.drugbank.com/drugs/DB05220
    Investigational

    Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.

  5. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase enzyme (ASPA). … [L43567] The FDA has granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of patients with Canavan disease.[L43572]

  6. Drug

    Pipequaline

    go.drugbank.com/drugs/DB13991
    Experimental

    Pipequaline has a similar pharmacological profile to the reported for the benzodiazepines. … Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic.

  7. Drug

    AEG35156

    go.drugbank.com/drugs/DB06184
    Investigational

    XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis. … This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis.

  8. Drug

    Tyramine

    go.drugbank.com/drugs/DB08841
    InvestigationalNutraceutical

    An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects. … Tyramine acts by inducing the release of catecholamine.

  9. Drug

    AeroLEF

    go.drugbank.com/drugs/DB05000
    Investigational

    AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain. … AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia

  10. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    [A187120] An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative breast cancer, and demonstrated promising synergistic effects.[A187123] … The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects.